<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PPAR Res</journal-id><journal-id journal-id-type="publisher-id">PPAR</journal-id><journal-title>PPAR Research</journal-title><issn pub-type="ppub">1687-4757</issn><issn pub-type="epub">1687-4765</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19266048</article-id><article-id pub-id-type="pmc">2650079</article-id><article-id pub-id-type="doi">10.1155/2008/635680</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Protective Actions of PPAR-<italic>&#x003b3;</italic> Activation in Renal Endothelium</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Westerweel</surname><given-names>Peter E.</given-names></name><xref ref-type="aff" rid="I1"><sup>1, 2</sup></xref><xref ref-type="aff" rid="I2"/></contrib><contrib contrib-type="author"><name><surname>Verhaar</surname><given-names>Marianne C.</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Vascular Medicine, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands</aff><aff id="I2"><sup>2</sup>Department of Internal Medicine, St. Antonius Hospital, Koekoekslaan 1, 3435 CM Nieuwegein, The Netherlands</aff><author-notes><corresp id="cor1">*Marianne C. Verhaar: <email>m.c.verhaar@umcutrecht.nl</email></corresp><fn fn-type="other"><p>Recommended by Nigel Brunskill</p></fn></author-notes><pub-date pub-type="ppub"><year>2008</year></pub-date><pub-date pub-type="epub"><day>26</day><month>2</month><year>2009</year></pub-date><volume>2008</volume><elocation-id>635680</elocation-id><history><date date-type="received"><day>15</day><month>9</month><year>2008</year></date><date date-type="accepted"><day>8</day><month>12</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 P. E. Westerweel and M. C. Verhaar.</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>Renal endothelial damage is pivotal in the initiation and progression of renal disease. Damaged renal endothelium may be regenerated through proliferation of local endothelium and circulation-derived endothelial progenitor cells. Activation of the PPAR-<italic>&#x003b3;</italic>-receptors present on endothelial cells affects their cellular behavior. Proliferation, apoptosis, migration, and angiogenesis by endothelial cells are modulated, but may involve both stimulation and inhibition depending on the specific circumstances.  PPAR-<italic>&#x003b3;</italic>-receptor activation stimulates the production of nitric oxide, C-type natriuretic peptide, and superoxide dismutase, while endothelin-1 production is inhibited. Together, they augment endothelial function, resulting in blood pressure lowering and direct renoprotective effects. The presentation of adhesion molecules and release of cytokines recruiting inflammatory cells are inhibited by PPAR-<italic>&#x003b3;</italic>-agonism. Finally, PPAR-<italic>&#x003b3;</italic>-receptors are also found on endothelial progenitor cells and PPAR-<italic>&#x003b3;</italic>-agonists stimulate progenitor-mediated endothelial repair. Together, the stimulatory effects of PPAR-<italic>&#x003b3;</italic>-agonism on endothelium make an important contribution to the beneficial actions of PPAR-<italic>&#x003b3;</italic>-agonists on renal disease.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. INTRODUCTION</title><p>PPAR-<italic>&#x003b3;</italic>-agonists are widely used for their insulin-sensitizingactions in the treatment of type 2 diabetes mellitus, but have additionaltherapeutic potential beyond the metabolic effects. Currently, the clinicallymost used PPAR-<italic>&#x003b3;</italic>-agonistic drugs are the thiazolidinediones (TZDs). PPAR-<italic>&#x003b3;</italic>-agonists may favorably affect the course of renaldisease in both diabetic and nondiabetic conditions [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>]. Innondiabetic animals, beneficial effects have been shown for anti-GBMantibody-induced crescentic glomerulonephritis [<xref ref-type="bibr" rid="B3">3</xref>],passive Heymann nephritis [<xref ref-type="bibr" rid="B4">4</xref>],the development of glomerulosclerosis after 5/6 nephrectomy [<xref ref-type="bibr" rid="B5">5</xref>],renal ischemia-reperfusion induced damage [<xref ref-type="bibr" rid="B6">6</xref>], and anti-Thy-1-glomerulonephritis [<xref ref-type="bibr" rid="B7">7</xref>]. Onepotential mechanism is the modulation of endothelial cell function throughactivation of PPAR-<italic>&#x003b3;</italic> receptors, which are expressed on glomerularendothelium [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>]. Inresponse to injury, the endothelial expression of PPAR-<italic>&#x003b3;</italic>-receptors may beincreased, for example, as transiently occurs after ischemia- reperfusion [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>]. Treatment with PPAR-<italic>&#x003b3;</italic>-agonists also increases the expression of PPAR-<italic>&#x003b3;</italic>-receptorson renal endothelium in both the glomerulus and the capillary endothelium ofthe medullary vasa recta [<xref ref-type="bibr" rid="B10">10</xref>]. Therelevance for renal disease of activating the PPAR-<italic>&#x003b3;</italic>-receptors on renal endotheliumis becoming increasingly clear and is the focus of this review.</p></sec><sec sec-type="section" id="sec2"><title>2. THE ROLE OF ENDOTHELIUM IN RENAL DISEASE</title><p>Renal microvascular endothelial injury is a pivotal pathogenic factor forvarious renal diseases. Renal disease conditions involving prominentendothelial damage include ischemic nephropathy, glomerulonephritis,interstitial nephritis, and allograft rejection [<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>]. Endothelial dysfunction and attenuated angiogenesis contribute to decliningrenal function with ageing [<xref ref-type="bibr" rid="B13">13</xref>] and the pathogenesis and progression of chronic kidney disease [<xref ref-type="bibr" rid="B11">11</xref>]. Themicrovascular endothelium, by the release of endothelium-derived factors suchas nitric oxide (NO) and as a critical component of the glomerular filtrationbarrier, exerts important protection against progressive renal damage. Endothelialdysfunction results in increased permeability causing passage of macromolecules(microalbuminuria), which is considered to be the earliest renal sign ofvascular dysfunction [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>]. Endothelial dysfunction has been shown to predict susceptibility to renaldamage in a rat renal injury model [<xref ref-type="bibr" rid="B16">16</xref>].</p><p>Progression of renaldisease does not only depend on the degree of microvascular endothelial injury,but also on the effectiveness of endothelial repair. Impaired glomerular capillary repair was foundto be associated with the development of glomerulosclerosis and renal failure [<xref ref-type="bibr" rid="B17">17</xref>]. During experimentalglomerulonephritis, angiogenic factors such as VEGF and bFGF are released,which stimulate endothelial regeneration [<xref ref-type="bibr" rid="B18">18</xref>&#x02013;<xref ref-type="bibr" rid="B20">20</xref>]. Blocking the VEGF-induced endothelial repair with a VEGF-antagonist interfereswith renal recovery and results in progressive renal impairment [<xref ref-type="bibr" rid="B21">21</xref>]. Consistently, progressive renal disease isassociated with reduced expression of angiogenic growth factors and enhancedexpression of antiangiogenic factors [<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>]. The glomerular endothelium can recover from injury by replacing lost ordamaged endothelial cells, in part through proliferation of local endothelium,stimulated by the release of angiogenic growth factors [<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>]. We [<xref ref-type="bibr" rid="B24">24</xref>&#x02013;<xref ref-type="bibr" rid="B26">26</xref>] and others [<xref ref-type="bibr" rid="B27">27</xref>] have observed in both human and experimental animal studies that damagedglomerular endothelium may also be regenerated from circulating bone marrow-derivedendothelial progenitor cells. Endothelial progenitor cells incorporate into thedamaged glomerulus, differentiate into mature endothelial cells, and eventuallyfully integrate into the resident endothelium [<xref ref-type="bibr" rid="B26">26</xref>].</p><p>Enhancing renal endothelialrepair offers therapeutic potential. Stimulating angiogenesis withVEGF-treatment augments capillary repair and renal recovery afterglomerulonephritis [<xref ref-type="bibr" rid="B19">19</xref>]. Enhancing NO production by supplementing the substrate L-arginine improves theclinical course of anti-Thy-1-glomerulonephritis [<xref ref-type="bibr" rid="B28">28</xref>]. Infusion of unselected bone marrow cells ameliorates experimental progressiveglomerulosclerosis [<xref ref-type="bibr" rid="B29">29</xref>]. Intrarenal administration of endothelialprogenitor cells attenuates endothelial injury and mesangial activation inexperimental glomerulonephritis [<xref ref-type="bibr" rid="B30">30</xref>].</p></sec><sec sec-type="section" id="sec3"><title>3. THE ROLE OF PPAR-<italic>&#x003b3;</italic>-RECEPTORS INVASCULAR DEVELOPMENT AND REMODELING</title><p>Phenotypicalstudies in humans and animals with genetic mutations in the PPAR-<italic>&#x003b3;</italic>-receptorimply a role in the regulation of vascular function and remodeling. In humanswith dominant-negative heterozygous mutations in the PPAR-<italic>&#x003b3;</italic>-receptor causing animpaired capacity for transcriptional activation, diabetes and alsohypertension occur at an unusually young age [<xref ref-type="bibr" rid="B31">31</xref>]. Heterozygous knockout mice haveincreased insulin sensitivity [<xref ref-type="bibr" rid="B32">32</xref>] and decreased fat mass [<xref ref-type="bibr" rid="B33">33</xref>], but do not have a vascular phenotype [<xref ref-type="bibr" rid="B34">34</xref>]. However, but PPAR-<italic>&#x003b3;</italic>-null mice areembryonically lethal due to placental dysfunction, characterized by defectivetrophoblast differentiation and markedly impaired placental vascularization [<xref ref-type="bibr" rid="B34">34</xref>]. A surviving PPAR-<italic>&#x003b3;</italic>-knockoutmouse that was supplementedwith a wild-type placenta developed an apparently normal vascular system duringfurther embryogenesis, but died some days after birth due to a combination ofpathologies, including severe lipodystrophic changes and hemorrhages [<xref ref-type="bibr" rid="B34">34</xref>]. In a conditional knockoutmodel using a cre-lox system to save floxed PPAR-<italic>&#x003b3;</italic>-knockout mice from embryoniclethality by preserving PPAR-<italic>&#x003b3;</italic>-function in the trophoblast marked lipodystrophywas also observed, together with insulin resistance. Surprisingly, these micewere hypotensive and showed increased endothelium-dependent relaxation inresponse to acetylcholine [<xref ref-type="bibr" rid="B35">35</xref>]. In the latter study, PPAR-<italic>&#x003b3;</italic>-functionwas deficient in all cell types. Mice in which PPAR-<italic>&#x003b3;</italic>-function was selectivelyknocked out in endothelial cells only using again a cre-lox system were foundto be hypertensive when fed a high-fat diet [<xref ref-type="bibr" rid="B36">36</xref>]. Also, in mice with a nonlethal-dominantnegative mutation in the PPAR-<italic>&#x003b3;</italic>-receptor, endothelium-dependent blood vessel dilatationis impaired, while the endothelium is more sensitive to endothelin-1-inducedvasoconstriction [<xref ref-type="bibr" rid="B37">37</xref>]. Superoxide levels in thesemice are elevated and treatment with a superoxide scavenger can reverse theimpaired endothelial vasodilation, highlighting the pivotal role of increasedradical formation [<xref ref-type="bibr" rid="B37">37</xref>]. Cerebral arterioles werehypertrophied with a decrease in luminal diameters, indicative of adverseinward vascular remodeling [<xref ref-type="bibr" rid="B37">37</xref>]. Of note, dominant negativePPAR-<italic>&#x003b3;</italic>-mutations were found not to be fully selective, therefore, it cannot beexcluded that some of the effects observed in the knockout systems areattributable to PPAR-<italic>&#x003b3;</italic>-receptor-independent signaling, in particular throughthe alternative PPAR-receptors [<xref ref-type="bibr" rid="B38">38</xref>].</p></sec><sec sec-type="section" id="sec4"><title>4. EFFECTS OF PPAR-<italic>&#x003b3;</italic>-ACTIVATION ONENDOTHELIAL PROLIFERATION, MIGRATION,ANGIOGENESIS, AND APOPTOSIS</title><p>Reports on the directeffects of PPAR-<italic>&#x003b3;</italic>-agonist treatment on proliferation, migration, and angiogenicnetwork formation of cultured endothelial cells showed variable results. Fukunagaet al. demonstrated increased proliferation with both troglitazone andpioglitazone in four different endothelial cell lines [<xref ref-type="bibr" rid="B39">39</xref>]. Incontrast, two other studies found troglitazone to inhibit proliferation ofmacrovascular endothelial cells [<xref ref-type="bibr" rid="B40">40</xref>] and human umbilical vein endothelial cells [<xref ref-type="bibr" rid="B41">41</xref>]. Rosiglitazonewas shown also to inhibit proliferation in one study [<xref ref-type="bibr" rid="B42">42</xref>], whileanother study found no effect at all [<xref ref-type="bibr" rid="B40">40</xref>].</p><p>VEGF-induced endothelialmigration was found to be inhibited by PPAR-<italic>&#x003b3;</italic>-agonists troglitazone andciglitazone, which was mediated by inhibition of Akt [<xref ref-type="bibr" rid="B43">43</xref>]. Thisis in line with the reduced migration and inhibition of angiogenic network formationby PPAR-<italic>&#x003b3;</italic>-agonism observed by Xin et al [<xref ref-type="bibr" rid="B44">44</xref>]. However,in the study by Fukunaga et al., troglitazone stimulated both endothelial cellmigration and proliferation, resulting in accelerated coverage of a disruptedendothelial monolayer in a wound healing assay [<xref ref-type="bibr" rid="B39">39</xref>]. Also,Biscetti et al. found stimulation of endothelial network formation with PPAR-<italic>&#x003b3;</italic>activation using the GW1929 compound, mainly through a VEGF-dependent mechanism [<xref ref-type="bibr" rid="B45">45</xref>].</p><p>In vitro effects of PPAR-<italic>&#x003b3;</italic>-agonismon endothelial cell apoptosis have been similarly variable. Both spontaneousand TNF-alpha-induced endothelial apoptosis were shown to be inhibited byvarious thiazolidinedione PPAR-<italic>&#x003b3;</italic>-agonists [<xref ref-type="bibr" rid="B46">46</xref>] and troglitazone was found to markedly reduce apoptosis in serum-starvedendothelial cells [<xref ref-type="bibr" rid="B47">47</xref>], while another study observed induction of apoptosis using bothciglitazone and PPAR-<italic>&#x003b3;</italic>-receptor overexpression [<xref ref-type="bibr" rid="B48">48</xref>]. In several studies, the endogenous PPAR-<italic>&#x003b3;</italic> ligand 15-deoxy-delta12,14-prostaglandin J2 (15d-PGJ2)-induced endothelialcell apoptosis [<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B49">49</xref>], but it is important to note that in vascular endothelial cells, theeffects of 15d-PGJ2 may be independentof PPAR-<italic>&#x003b3;</italic>-receptor activation [<xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B50">50</xref>].</p><p>Taken together, it is clearthat PPAR-<italic>&#x003b3;</italic>-agonists may modulate endothelial proliferation, migration,angiogenesis, and apoptosis in vitro, but that this may result in bothstimulation and inhibition. The factors that determine whether treatment with a PPAR-<italic>&#x003b3;</italic>-agonist results in a stimulatory or inhibitory effect on endothelial cells remain largely unidentified. This may involve PPAR-<italic>&#x003b3;</italic>-receptor-independent effects asreported for 15d-PGJ2 [<xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B50">50</xref>] and also withthe various TZDs [<xref ref-type="bibr" rid="B45">45</xref>]. Fukunaga et al. posed that a concentration dependency may explain some of theobserved discrepancies, as they observed stimulation of DNA-synthesis at low PPAR-<italic>&#x003b3;</italic>-agonistdosages and inhibition at higher dosages [<xref ref-type="bibr" rid="B39">39</xref>]. However, this cannot explain all of the divergent findings.</p><p>Invivo studies in diabetic animals with impaired angiogenesis in response toperipheral ischemia showed that treatment with PPAR-<italic>&#x003b3;</italic>-agonist pioglitazoneaugmented the angiogenic response and increased blood flow recovery [<xref ref-type="bibr" rid="B51">51</xref>]. In rats with experimentalfocal cerebral ischemia, PPAR-<italic>&#x003b3;</italic>-agonist treatment stimulated local angiogenesisand improved functional neurological recovery [<xref ref-type="bibr" rid="B52">52</xref>]. In contrast, PPAR-<italic>&#x003b3;</italic>-agonisttreatment inhibited pathological choroidial and retinal neovascularization [<xref ref-type="bibr" rid="B53">53</xref>] and suppressed tumor growthand metastasis by inhibiting tumor angiogenesis in several primary tumors, inpart through decreasing VEGF-production by tumor cells and blocking the productionof angiogenic ELR+CXC-chemokines, mediated through antagonizing NF-kappaBactivation [<xref ref-type="bibr" rid="B54">54</xref>, <xref ref-type="bibr" rid="B55">55</xref>]. These findings suggest that PPAR-<italic>&#x003b3;</italic>-agonism may differentially affectneovascularization with inhibition of pathological neovascularization andaugmentation of physiological neovascularization. This is in line with the invitro observations of both stimulatory and inhibitory actions.</p></sec><sec sec-type="section" id="sec5"><title>5. EFFECTS OF PPAR-<italic>&#x003b3;</italic>-ACTIVATION ONENDOTHELIAL DYSFUNCTION</title><p>Endothelial integrity doesnot only rely on the number of cells, but also on their function. NO-productionis a key component of endothelial function. NO stimulates vasodilation, inhibitsinflammation, prevents platelet activation, and scavenges radicals [<xref ref-type="bibr" rid="B56">56</xref>]. Invitro studies on the effect of PPAR-<italic>&#x003b3;</italic>-activation have consistently shown astimulating effect on NO production by endothelial cells [<xref ref-type="bibr" rid="B57">57</xref>&#x02013;<xref ref-type="bibr" rid="B60">60</xref>]. The observation that siRNA against PPAR-<italic>&#x003b3;</italic> blocked the increase inNO-production confirmed that this effectis PPAR-<italic>&#x003b3;</italic>-receptor mediated [<xref ref-type="bibr" rid="B59">59</xref>]. Inboth experimental animal studies and in humans, PPAR-<italic>&#x003b3;</italic>-activation has beenshown to augment systemic NO-production and endothelial function. In diabeticrats, PPAR-<italic>&#x003b3;</italic>-agonist treatment restoredimpaired endothelium-dependent arterial relaxation by increasing NO-productionwhile reducing oxidative stress [<xref ref-type="bibr" rid="B61">61</xref>]. Inhealthy human subjects, a single dose of troglitazone increased NO-dependentendothelial function measured by venous occlusion plethysmography of theforearm and nitrite levels [<xref ref-type="bibr" rid="B62">62</xref>]. Innondiabetic patients with hypertension or hypercholesterolemia, endothelialfunction was improved with pioglitazone [<xref ref-type="bibr" rid="B63">63</xref>]. Intype 2 diabetic patients, vascular resistance was shown to be reduced withtroglitazone treatment [<xref ref-type="bibr" rid="B64">64</xref>, <xref ref-type="bibr" rid="B65">65</xref>] and in type 2 diabetic patients with angina pectoris, troglitazone reduced the frequency of anginapectoris with improving endothelial function [<xref ref-type="bibr" rid="B66">66</xref>]. Rosiglitazone attenuated the detrimental effectsof the presence of diabetes on NO-production measured directly using anintravital probe and by assessing blood flow in the peripheral skin [<xref ref-type="bibr" rid="B67">67</xref>]. Long-termtreatment with pioglitazone resulted in a reduced pulse wave velocity,indicative of reduced vascular stiffness [<xref ref-type="bibr" rid="B68">68</xref>]. In renal transplant recipients, PPAR-<italic>&#x003b3;</italic>-agonisttreatment enhanced endothelial function [<xref ref-type="bibr" rid="B69">69</xref>].</p><p>Importantly, the observedbeneficial effects on systemic endothelial function were found to extend to improving intrarenalNO-production. In human type 2 diabetic patients, rosiglitazone treatmentincreased intrarenal NO levels, which was associated with improvement of renalhemodynamics and reduction of proteinuria [<xref ref-type="bibr" rid="B70">70</xref>]. This is in line with animal studies. In obese Zucker rats, PPAR-<italic>&#x003b3;</italic>-agonisttreatment lowered blood pressure and ameliorated abnormal pressure natriuresis in association withincreased renal NO-metabolite nitrite/nitrateproduction [<xref ref-type="bibr" rid="B71">71</xref>]. Inobese hypertensive Sprague-Dawley rats, PPAR-<italic>&#x003b3;</italic>-agonist treatment also reduced bloodpressure, increased NO-metabolite nitrite/nitrate excretion, and reducedexcretion of oxidative-stress associated urinary isoprostanes and lipidperoxides [<xref ref-type="bibr" rid="B72">72</xref>]. Inthe kidneys of these rats, eNOS expression was increased while the pathologicalincrease in p47phox and gp91phox associated with obesity was attenuated [<xref ref-type="bibr" rid="B72">72</xref>].</p><p>Differences have beenobserved between the various PPAR-<italic>&#x003b3;</italic>-activating compounds in the signaling levelat which NO-production is stimulated. The NO producing enzyme endothelialnitric oxide synthase (eNOS) is not only regulated at the level oftranscription and translation, but also has multiple phosphorylation sites foractivation and deactivation of the enzyme and requires translocation to thecaveolae to associate with its cofactors and effectively produce NO [<xref ref-type="bibr" rid="B73">73</xref>, <xref ref-type="bibr" rid="B74">74</xref>]. Troglitazonehas been shown to enhance NO-production by increasing eNOS transcription andeNOS protein translation inisolated endothelial cells [<xref ref-type="bibr" rid="B58">58</xref>],while no effect was found at the transcriptional level for 15d-PGJ2 [<xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B58">58</xref>], pioglitazone [<xref ref-type="bibr" rid="B58">58</xref>], and ciglitazone [<xref ref-type="bibr" rid="B57">57</xref>]. 15d-PGJ2 and rosiglitazone, but notciglitazone, were found to stimulate eNOS-phophorylation at activation site ser-1177,thought to be mediated through increasing heat shock protein (hsp)-90association with eNOS [<xref ref-type="bibr" rid="B59">59</xref>]. Interestingly, there is a cross-talk betweenNO and PPAR-<italic>&#x003b3;</italic> pathways as NO has been shown to rapidly and dose-dependentlyincrease PPAR-<italic>&#x003b3;</italic>-binding, mediated by p38 MAPK activation [<xref ref-type="bibr" rid="B60">60</xref>].</p><p>Invivo, the stimulatory effect of PPAR-<italic>&#x003b3;</italic>-agonists rosiglitazone and pioglitazoneon endothelial NO-production was associated with increasedeNOS-phosphorylation, while eNOS mRNA and total protein levels were notaffected [<xref ref-type="bibr" rid="B51">51</xref>, <xref ref-type="bibr" rid="B75">75</xref>]. Rosiglitazone treatment has been shown toenhance NO-production through enhancement of cellular transport of arginine,the substrate for NO [<xref ref-type="bibr" rid="B76">76</xref>]. This is particularly relevant for renaldisease, as arginine transport was found to be markedly impaired in uremicconditions [<xref ref-type="bibr" rid="B77">77</xref>&#x02013;<xref ref-type="bibr" rid="B79">79</xref>].</p><p>PPAR-<italic>&#x003b3;</italic>-agonism favorablyaffects other endothelium-derived factors that act in conjunction with NO to maintainendothelial homeostasis. The release of C-type natriuretic peptide, anothervasodilatory peptide, by endothelial cells is increased by PPAR-<italic>&#x003b3;</italic>-agonisttreatment [<xref ref-type="bibr" rid="B39">39</xref>]. In addition, PPAR-<italic>&#x003b3;</italic>-agonist treatment increased Cu<sup>2+</sup> and  Zn<sup>2+</sup>-superoxidedismutase expression in cultured endothelial cells, thereby increasing their potentialfor oxygen radical scavenging [<xref ref-type="bibr" rid="B80">80</xref>, <xref ref-type="bibr" rid="B81">81</xref>]. Also, PPAR-<italic>&#x003b3;</italic>-agonist treatment decreasesthe production of radical oxygen species in endothelial cells [<xref ref-type="bibr" rid="B81">81</xref>, <xref ref-type="bibr" rid="B82">82</xref>], inpart through decreasing the expression of subunits of NADPH-oxidase [<xref ref-type="bibr" rid="B80">80</xref>, <xref ref-type="bibr" rid="B81">81</xref>].</p></sec><sec sec-type="section" id="sec6"><title>6. ANTIHYPERTENSIVE EFFECTSOF PPAR-<italic>&#x003b3;</italic>-AGONISM MEDIATED BYTHE ENDOTHELIUM</title><p>Improving NO-availabilityis thought to be a major mechanism mediating the blood pressure lowering effectof PPAR-<italic>&#x003b3;</italic>-agonist treatment. Pioglitazone treatment prevented hypertension and renal oxidative stressboth by reducing free-radical production and by increasing nitric oxideproduction [<xref ref-type="bibr" rid="B72">72</xref>]. No bloodpressure reduction was seen with PPAR-<italic>&#x003b3;</italic>-agonist treatment in rats alsoreceiving NO-inhibitor L-NAME [<xref ref-type="bibr" rid="B83">83</xref>]. However, other mechanisms may play a role in the anti-hypertensive effect of PPAR-<italic>&#x003b3;</italic>-agonisttreatment, such as effects on the contractility and proliferation of smoothmuscle cells [<xref ref-type="bibr" rid="B84">84</xref>].</p><p>A naturally occurringantagonist of NO is the vasoconstrictor endothelin-1, which is involved inatherosclerosis and hypertension [<xref ref-type="bibr" rid="B85">85</xref>]. PPAR-<italic>&#x003b3;</italic>-activation inhibits the production ofendothelin-1 from endothelial cells in vitro [<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B86">86</xref>&#x02013;<xref ref-type="bibr" rid="B88">88</xref>]. Intype 2 diabetic patients, pioglitazone treatment reduced urinary endothelin-1secretion, along with decreasing microalbuminuria [<xref ref-type="bibr" rid="B89">89</xref>]. Interestingly, in thisstudy, serum endothelin-1 levels were not affected, suggesting a specificpathogenic role for endothelin-1 secretion in the kidney [<xref ref-type="bibr" rid="B89">89</xref>]. In DOCA-salt hypertensive rats, TZD treatmentreduced endothelin-1 production and blunted radical oxygen species productionwith diminished hypertension progression and vascular remodeling [<xref ref-type="bibr" rid="B90">90</xref>]. Several studies show that theinhibitory effect of PPAR-<italic>&#x003b3;</italic>-activation on endothelin-1 secretion takes place atthe transcriptional level [<xref ref-type="bibr" rid="B86">86</xref>, <xref ref-type="bibr" rid="B87">87</xref>] andit was found to be NO-dependent [<xref ref-type="bibr" rid="B87">87</xref>]. Delerive et al. demonstratedthat PPAR-<italic>&#x003b3;</italic>-activation negatively interferes with the activator protein-1 signalingcascade, resulting in inhibition of thrombin-induced transcription ofendothelin-1 [<xref ref-type="bibr" rid="B88">88</xref>].</p><p>Inhypertension, increased production and secondary effects of angiotensin-II playa major role. In endothelial cells, angiotensin-II is a strong inducer ofNADPH-oxidase, resulting in the production of radical oxygen species [<xref ref-type="bibr" rid="B91">91</xref>]. Interestingly, there is across-talk between the Angiotensin-II and PPAR-<italic>&#x003b3;</italic> signaling pathways. Infusionof angiotensin-II downregulates PPAR-<italic>&#x003b3;</italic>-receptor expression in the vascular wall [<xref ref-type="bibr" rid="B92">92</xref>] and treatment with PPAR-<italic>&#x003b3;</italic>-agonistsabrogates many of the angiotensin-II pathophysiological effects [<xref ref-type="bibr" rid="B93">93</xref>]. Of note, angiotensin-II-receptor-1antagonists have been shown to act as partial PPAR-<italic>&#x003b3;</italic>-agonists [<xref ref-type="bibr" rid="B94">94</xref>].</p></sec><sec sec-type="section" id="sec7"><title>7. EFFECTS OF PPAR-<italic>&#x003b3;</italic>-ACTIVATION ONINFLAMMATORY CELL RECRUITMENT TOTHE ENDOTHELIUM</title><p>Endothelial cells form animportant barrier between the blood and peripheral tissues and regulate homing,adhesion, and transmigration of inflammatory cells. Upon activation,endothelial cells may further release inflammatory cytokines and expressadhesion molecules to attract inflammatory cells. PPAR-<italic>&#x003b3;</italic>-agonist treatmentinhibits the increased expression of adhesion molecules such as VCAM-1, ICAM-1,and E-selectin and release of inflammatory cytokines upon stimulation ofendothelial cells with PMA [<xref ref-type="bibr" rid="B95">95</xref>, <xref ref-type="bibr" rid="B96">96</xref>], TNF-<italic>&#x003b1;</italic> [<xref ref-type="bibr" rid="B95">95</xref>, <xref ref-type="bibr" rid="B97">97</xref>], IFN-<italic>&#x003b3;</italic> [<xref ref-type="bibr" rid="B98">98</xref>], IL-1<italic>&#x003b2;</italic> [<xref ref-type="bibr" rid="B99">99</xref>], LPS [<xref ref-type="bibr" rid="B96">96</xref>], microparticles [<xref ref-type="bibr" rid="B100">100</xref>], and high glucose [<xref ref-type="bibr" rid="B101">101</xref>]. In vitro studies confirmed that this resulted in decreasedadhesion of inflammatory cells to the endothelium [<xref ref-type="bibr" rid="B96">96</xref>, <xref ref-type="bibr" rid="B97">97</xref>, <xref ref-type="bibr" rid="B101">101</xref>, <xref ref-type="bibr" rid="B102">102</xref>]. In addition, a recent study showed that in activated primaryhuman brain endothelial cells, PPAR-<italic>&#x003b3;</italic>-activation resulted in a marked reductionof monocyte adhesion and in vitro transendothelial migration, mediated byinhibition of Rac1 and RhoA GTPases [<xref ref-type="bibr" rid="B102">102</xref>].  In vivo, troglitazone and 15d-PGJ2 reducedICAM-1 and VCAM-1 expressionon endothelial cells and reduced inflammatory cell homing to atheroscleroticplaques in a mouse model [<xref ref-type="bibr" rid="B103">103</xref>].</p></sec><sec sec-type="section" id="sec8"><title>8. EFFECTS OF PPAR-<italic>&#x003b3;</italic>-ACTIVATION ONENDOTHELIAL PROGENITOR CELLS</title><p>A recently uncovered effectof PPAR-<italic>&#x003b3;</italic>-agonists is the capacity to augment the level and function of endothelialprogenitor cells. PPAR-<italic>&#x003b3;</italic>-agonist treatment increases endothelialprogenitor cell levels in mice [<xref ref-type="bibr" rid="B104">104</xref>, <xref ref-type="bibr" rid="B105">105</xref>] andhumans [<xref ref-type="bibr" rid="B104">104</xref>, <xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B107">107</xref>]. A stimulatory effect on endothelialprogenitor cell outgrowth was also observed when cultured peripheral bloodmononuclear cells were exposed to PPAR-<italic>&#x003b3;</italic>-agonist treatment ex vivo [<xref ref-type="bibr" rid="B104">104</xref>, <xref ref-type="bibr" rid="B105">105</xref>, <xref ref-type="bibr" rid="B108">108</xref>, <xref ref-type="bibr" rid="B109">109</xref>], suggesting an effect on endothelial progenitor cell survival, adhesion,or differentiation. PPAR-<italic>&#x003b3;</italic>-agonist treatment largely prevented apoptosis of endothelial progenitorcells induced by CRP [<xref ref-type="bibr" rid="B109">109</xref>] and H<sub>2</sub>O<sub>2</sub> [<xref ref-type="bibr" rid="B105">105</xref>]. Based on marker expression patterns, thedifferentiation of endothelial progenitor cells toward the endothelial lineage appearsto be stimulated [<xref ref-type="bibr" rid="B104">104</xref>, <xref ref-type="bibr" rid="B108">108</xref>], while expression of smooth muscle cell markersis inhibited [<xref ref-type="bibr" rid="B104">104</xref>]. Pioglitazone inhibited detrimental effects ofangiotensin-II on endothelial progenitor cells, including inhibiting theinduction of cellular senescence of endothelial progenitor cells viadownregulation of the expression of angiotensin-II-receptor-1 and limiting the angiotensin-II-inducedincreased generation of peroxynitrate and superoxide by the NADPH-oxidasesubunit gp91phox [<xref ref-type="bibr" rid="B110">110</xref>].</p><p>Functionally,PPAR-<italic>&#x003b3;</italic>-agonist treatment was shown to stimulate angiogenic network formation byendothelial progenitor cells in vitro [<xref ref-type="bibr" rid="B109">109</xref>] and in vivo [<xref ref-type="bibr" rid="B105">105</xref>]. The adhesion capacity may be increased uponTZD-treatment [<xref ref-type="bibr" rid="B108">108</xref>, <xref ref-type="bibr" rid="B109">109</xref>]. In addition,endothelial progenitor cell-mediated reendothelialization of a denuded segmentof the femoral artery in mice was accelerated in PPAR-<italic>&#x003b3;</italic>-agonist treated animals [<xref ref-type="bibr" rid="B104">104</xref>]. Asendothelial progenitor cells may also participate in regeneration of damaged renalendothelium [<xref ref-type="bibr" rid="B26">26</xref>],we investigated a potential role for enhanced endothelial progenitor cell homingand glomerular incorporation by PPAR-<italic>&#x003b3;</italic>-agonist treatment [<xref ref-type="bibr" rid="B7">7</xref>]. However,using a rat allogenic bone marrow transplantation model, we could not detect aneffect on the number of incorporated circulation-derived glomerular endothelialcells in the recovering glomerulus with rosiglitazone treatment, althoughrosiglitazone did attenuate the clinical course of glomerulonephritis.</p></sec><sec sec-type="section" id="sec9"><title>9. CONCLUSIONS AND PERSPECTIVES</title><p>Activation of the PPAR-<italic>&#x003b3;</italic>-receptors present on renal endothelial cellsaffects their cellular behavior. Proliferation, apoptosis, migration, andangiogenesis by endothelial cells are modulated, but may involve both stimulation andinhibition depending on the specific circumstances. It remains unclear how thisbimodal potential of PPAR-<italic>&#x003b3;</italic>-agonists is regulated. An important consequence of PPAR-<italic>&#x003b3;</italic>-receptoractivation is the enhanced production of nitric oxide and C-type natriureticpeptide and superoxide dismutase, while endothelin-1 production is inhibited. Together, this improves the capacity of the endothelium to exert vasodilatory,anti-inflammatory, and antioxidative actions, resulting in blood pressurelowering and direct renoprotective effects. In addition, the presentation of adhesionmolecules and release of cytokines aimed at recruiting inflammatory cells toactivated endothelium is inhibited by PPAR-<italic>&#x003b3;</italic>-agonism. This may also in partaccount for the anti-inflammatory effects of PPAR-<italic>&#x003b3;</italic>-agonists, supplementary todirect effects on the inflammatory cells themselves. Finally, PPAR-<italic>&#x003b3;</italic>-receptorsare also found on endothelial progenitor cells and PPAR-<italic>&#x003b3;</italic>-agonist stimulateprogenitor-mediated endothelial repair, although definitive evidence that thisoccurs in the kidney is currently lacking.</p><p>Activation of other PPAR-receptors besides PPAR-<italic>&#x003b3;</italic> may also havebeneficial effects on the endothelium. Recently, selective agonists for PPAR-<italic>&#x003b2;</italic>/<italic>&#x003b4;</italic>were developed [<xref ref-type="bibr" rid="B111">111</xref>]. PPAR-<italic>&#x003b2;</italic>/<italic>&#x003b4;</italic> receptors are present on endothelium and stimulation with apharmacological PPAR-<italic>&#x003b2;</italic>/<italic>&#x003b4;</italic>-agonist was found to increase endothelial cellproliferation and angiogenesis in vitro and in vivo, mainly mediated throughVEGF [<xref ref-type="bibr" rid="B112">112</xref>]. Like PPAR-<italic>&#x003b3;</italic>-agonists, PPAR-<italic>&#x003b2;</italic>/<italic>&#x003b4;</italic>-agonists increase circulating endothelialprogenitor cell levels, augment endothelial progenitor cell function in vitro,and improve endothelial progenitor cell-mediated neovascularization of ischemictissue [<xref ref-type="bibr" rid="B113">113</xref>]. Also, much like PPAR-<italic>&#x003b3;</italic>-agonists, PPAR-<italic>&#x003b2;</italic>/<italic>&#x003b4;</italic>-agonist treatment reduced theexpression of adhesion molecules and monocyte binding to activated endothelialcells [<xref ref-type="bibr" rid="B114">114</xref>].</p><p>Currently, PPAR-<italic>&#x003b3;</italic>-agonist treatment is not standard clinical practice innondiabetic renal patients. As shown in this review, experimental studiesindicate that stimulatory effects of PPAR-<italic>&#x003b3;</italic>-agonism on endothelium may provideadditional benefit in nondiabetic renal disease. Together with otherpotentially therapeutic effects independent of the insulin-sensitizing actionsuch as the anti-inflammatory actions, this provides a rationale for furtherclinical evaluation in nondiabetic renal patients. For patients with diabetickidney disease, a pressing question is whether glycemic control with a TZD issuperior to other antidiabetic drugs for preventing the decline of renalfunction. To date, only retrospective studies, post hoc analyses, and pilot studies are availableto help answer this question. Trials designed to specifically evaluate thisquestion have yet to be performed.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>P. E. Westerweel is supported by ZonMw AGIKO Grant no. 2007/12579. M. C. Verhaar is supported by NWO Vidi Grant no. 016.096.359.</p></ack><ref-list><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Breyer</surname><given-names>MD</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease</article-title><source><italic>Kidney International</italic></source><year>2001</year><volume>60</volume><issue>1</issue><fpage>14</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">11422732</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sarafidis</surname><given-names>PA</given-names></name><name><surname>Bakris</surname><given-names>GL</given-names></name></person-group><article-title>Protection of the kidney by thiazolidinediones: an assessment from bench to bedside</article-title><source><italic>Kidney International</italic></source><year>2006</year><volume>70</volume><issue>7</issue><fpage>1223</fpage><lpage>1233</lpage><pub-id pub-id-type="pmid">16883325</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haraguchi</surname><given-names>K</given-names></name><name><surname>Shimura</surname><given-names>H</given-names></name><name><surname>Onaya</surname><given-names>T</given-names></name></person-group><article-title>Suppression of experimental crescentic glomerulonephritis by peroxisome proliferator-activated receptor (PPAR)<italic>&#x003b3;</italic> activators</article-title><source><italic>Clinical and Experimental Nephrology</italic></source><year>2003</year><volume>7</volume><issue>1</issue><fpage>27</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">14586740</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benigni</surname><given-names>A</given-names></name><name><surname>Zoja</surname><given-names>C</given-names></name><name><surname>Tomasoni</surname><given-names>S</given-names></name><etal/></person-group><article-title>Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-<italic>&#x003b3;</italic> agonist: molecular mechanism of the antiproteinuric effect of pioglitazone</article-title><source><italic>Journal of the American Society of Nephrology</italic></source><year>2006</year><volume>17</volume><issue>6</issue><fpage>1624</fpage><lpage>1632</lpage><pub-id pub-id-type="pmid">16687628</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>L-J</given-names></name><name><surname>Marcantoni</surname><given-names>C</given-names></name><name><surname>Linton</surname><given-names>MF</given-names></name><name><surname>Fazio</surname><given-names>S</given-names></name><name><surname>Fogo</surname><given-names>AB</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor-<italic>&#x003b3;</italic> agonist troglitazone protects against nondiabetic glomerulosclerosis in rats</article-title><source><italic>Kidney International</italic></source><year>2001</year><volume>59</volume><issue>5</issue><fpage>1899</fpage><lpage>1910</lpage><pub-id pub-id-type="pmid">11318962</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sivarajah</surname><given-names>A</given-names></name><name><surname>Chatterjee</surname><given-names>PK</given-names></name><name><surname>Patel</surname><given-names>NSA</given-names></name><etal/></person-group><article-title>Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury</article-title><source><italic>The American Journal of Nephrology</italic></source><year>2003</year><volume>23</volume><issue>4</issue><fpage>267</fpage><lpage>276</lpage></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Westerweel</surname><given-names>PE</given-names></name><name><surname>den Ouden</surname><given-names>K</given-names></name><name><surname>Nguyen</surname><given-names>TQ</given-names></name><name><surname>Goldschmeding</surname><given-names>R</given-names></name><name><surname>Joles</surname><given-names>JA</given-names></name><name><surname>Verhaar</surname><given-names>MC</given-names></name></person-group><article-title>Amelioration of anti-Thy1-glomerulonephritis by PPAR-<italic>&#x003b3;</italic> agonism without increase of endothelial progenitor cell homing</article-title><source><italic>The American Journal of Physiology</italic></source><year>2008</year><volume>294</volume><issue>2</issue><fpage>F379</fpage><lpage>F384</lpage></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsuyama</surname><given-names>M</given-names></name><name><surname>Yoshimura</surname><given-names>R</given-names></name><name><surname>Hase</surname><given-names>T</given-names></name><etal/></person-group><article-title>Expression of peroxisome proliferator-activated receptor-<italic>&#x003b3;</italic> in renal ischemia-reperfusion injury</article-title><source><italic>Transplantation Proceedings</italic></source><year>2005</year><volume>37</volume><issue>4</issue><fpage>1684</fpage><lpage>1685</lpage><pub-id pub-id-type="pmid">15919430</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoshimura</surname><given-names>R</given-names></name><name><surname>Matsuyama</surname><given-names>M</given-names></name><name><surname>Segawa</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Study of peroxisome proliferator-activated receptor (PPAR)-<italic>&#x003b3;</italic> in renal ischemia-reperfusion injury</article-title><source><italic>Transplantation Proceedings</italic></source><year>2004</year><volume>36</volume><issue>7</issue><fpage>1946</fpage><lpage>1948</lpage><pub-id pub-id-type="pmid">15518707</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Schneider</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>L</given-names></name><name><surname>Breyer</surname><given-names>RM</given-names></name><name><surname>Breyer</surname><given-names>MD</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor-<italic>&#x003b3;</italic> activity is associated with renal microvasculature</article-title><source><italic>The American Journal of Physiology</italic></source><year>2001</year><volume>281</volume><issue>6</issue><fpage>F1036</fpage><lpage>F1046</lpage></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamanaka</surname><given-names>N</given-names></name><name><surname>Shimizu</surname><given-names>A</given-names></name></person-group><article-title>Role of glomerular endothelial damage in progressive renal disease</article-title><source><italic>Kidney and Blood Pressure Research</italic></source><year>1999</year><volume>22</volume><issue>1-2</issue><fpage>13</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">10352403</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reinders</surname><given-names>MEJ</given-names></name><name><surname>Rabelink</surname><given-names>TJ</given-names></name><name><surname>Briscoe</surname><given-names>DM</given-names></name></person-group><article-title>Angiogenesis and endothelial cell repair in renal disease and allograft rejection</article-title><source><italic>Journal of the American Society of Nephrology</italic></source><year>2006</year><volume>17</volume><issue>4</issue><fpage>932</fpage><lpage>942</lpage><pub-id pub-id-type="pmid">16481411</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>DA</given-names></name><name><surname>Mu</surname><given-names>W</given-names></name><name><surname>Price</surname><given-names>KL</given-names></name><name><surname>Johnson</surname><given-names>RJ</given-names></name></person-group><article-title>Blood vessels and the aging kidney</article-title><source><italic>Nephron Experimental Nephrology</italic></source><year>2005</year><volume>101</volume><issue>3</issue><fpage>e95</fpage><lpage>e99</lpage><pub-id pub-id-type="pmid">16043968</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garg</surname><given-names>JP</given-names></name><name><surname>Bakris</surname><given-names>GL</given-names></name></person-group><article-title>Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease</article-title><source><italic>Vascular Medicine</italic></source><year>2002</year><volume>7</volume><issue>1</issue><fpage>35</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">12083733</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bakris</surname><given-names>GL</given-names></name></person-group><article-title>Clinical importance of microalbuminuria in diabetes and hypertension</article-title><source><italic>Current Hypertension Reports</italic></source><year>2004</year><volume>6</volume><issue>5</issue><fpage>352</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">15341686</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gschwend</surname><given-names>S</given-names></name><name><surname>Buikema</surname><given-names>H</given-names></name><name><surname>Navis</surname><given-names>G</given-names></name><name><surname>Henning</surname><given-names>RH</given-names></name><name><surname>de Zeeuw</surname><given-names>D</given-names></name><name><surname>van Dokkum</surname><given-names>RPE</given-names></name></person-group><article-title>Endothelial dilatory function predicts individual susceptibility to renal damage in the 5/6 nephrectomized rat</article-title><source><italic>Journal of the American Society of Nephrology</italic></source><year>2002</year><volume>13</volume><issue>12</issue><fpage>2909</fpage><lpage>2915</lpage><pub-id pub-id-type="pmid">12444209</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>A</given-names></name><name><surname>Kitamura</surname><given-names>H</given-names></name><name><surname>Masuda</surname><given-names>Y</given-names></name><name><surname>Ishizaki</surname><given-names>M</given-names></name><name><surname>Sugisaki</surname><given-names>Y</given-names></name><name><surname>Yamanaka</surname><given-names>N</given-names></name></person-group><article-title>Rare glomerular capillary regeneration and subsequent capillary regression with endothelial cell apoptosis in progressive glomerulonephritis</article-title><source><italic>The American Journal of Pathology</italic></source><year>1997</year><volume>151</volume><issue>5</issue><fpage>1231</fpage><lpage>1239</lpage><pub-id pub-id-type="pmid">9358748</pub-id></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iruela-Arispe</surname><given-names>L</given-names></name><name><surname>Gordon</surname><given-names>K</given-names></name><name><surname>Hugo</surname><given-names>C</given-names></name><etal/></person-group><article-title>Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis</article-title><source><italic>The American Journal of Pathology</italic></source><year>1995</year><volume>147</volume><issue>6</issue><fpage>1715</fpage><lpage>1727</lpage><pub-id pub-id-type="pmid">7495296</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Masuda</surname><given-names>Y</given-names></name><name><surname>Shimizu</surname><given-names>A</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><etal/></person-group><article-title>Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis</article-title><source><italic>The American Journal of Pathology</italic></source><year>2001</year><volume>159</volume><issue>2</issue><fpage>599</fpage><lpage>608</lpage><pub-id pub-id-type="pmid">11485918</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miyamoto</surname><given-names>K</given-names></name><name><surname>Kitamoto</surname><given-names>Y</given-names></name><name><surname>Tokunaga</surname><given-names>H</given-names></name><etal/></person-group><article-title>Protective effect of vascular endothelial growth factor/vascular permeability factor 165 and 121 on glomerular endothelial cell injury in the rat</article-title><source><italic>Laboratory Investigation</italic></source><year>2004</year><volume>84</volume><issue>9</issue><fpage>1126</fpage><lpage>1136</lpage><pub-id pub-id-type="pmid">15195119</pub-id></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ostendorf</surname><given-names>T</given-names></name><name><surname>Kunter</surname><given-names>U</given-names></name><name><surname>Eitner</surname><given-names>F</given-names></name><etal/></person-group><article-title>VEGf<sub>165</sub> mediates glomerular endothelial repair</article-title><source><italic>The Journal of Clinical Investigation</italic></source><year>1999</year><volume>104</volume><issue>7</issue><fpage>913</fpage><lpage>923</lpage><pub-id pub-id-type="pmid">10510332</pub-id></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>D-H</given-names></name><name><surname>Hughes</surname><given-names>J</given-names></name><name><surname>Mazzali</surname><given-names>M</given-names></name><name><surname>Schreiner</surname><given-names>GF</given-names></name><name><surname>Johnson</surname><given-names>RJ</given-names></name></person-group><article-title>Impaired angiogenesis in the remnant kidney model&#x02014;part II: vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function</article-title><source><italic>Journal of the American Society of Nephrology</italic></source><year>2001</year><volume>12</volume><issue>7</issue><fpage>1448</fpage><lpage>1457</lpage><pub-id pub-id-type="pmid">11423573</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>DH</given-names></name><name><surname>Joly</surname><given-names>AH</given-names></name><name><surname>Oh</surname><given-names>SW</given-names></name><etal/></person-group><article-title>Impaired angiogenesis in the remnant kidney model&#x02014;part I: potential role of vascular endothelial growth factor and thrombospondin-1</article-title><source><italic>Journal of the American Society of Nephrology</italic></source><year>2001</year><volume>12</volume><issue>7</issue><fpage>1434</fpage><lpage>1447</lpage><pub-id pub-id-type="pmid">11423572</pub-id></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rookmaaker</surname><given-names>MB</given-names></name><name><surname>Tolboom</surname><given-names>H</given-names></name><name><surname>Goldschmeding</surname><given-names>R</given-names></name><name><surname>Zwaginga</surname><given-names>J-J</given-names></name><name><surname>Rabelink</surname><given-names>TJ</given-names></name><name><surname>Verhaar</surname><given-names>MC</given-names></name></person-group><article-title>Bone marrow-derived cells contribute to endothelial repair after thrombotic microangiopathy</article-title><source><italic>Blood</italic></source><year>2002</year><volume>99</volume><issue>3</issue><fpage>p. 1095</fpage></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rookmaaker</surname><given-names>MB</given-names></name><name><surname>Smits</surname><given-names>AM</given-names></name><name><surname>Tolboom</surname><given-names>H</given-names></name><etal/></person-group><article-title>Bone-marrow-derived cells contribute to glomerular endothelial repair in experimental glomerulonephritis</article-title><source><italic>The American Journal of Pathology</italic></source><year>2003</year><volume>163</volume><issue>2</issue><fpage>553</fpage><lpage>562</lpage><pub-id pub-id-type="pmid">12875975</pub-id></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rookmaaker</surname><given-names>MB</given-names></name><name><surname>Verhaar</surname><given-names>MC</given-names></name><name><surname>Van Zonneveld</surname><given-names>AJ</given-names></name><name><surname>Rabelink</surname><given-names>TJ</given-names></name></person-group><article-title>Progenitor cells in the kidney: biology and therapeutic perspectives</article-title><source><italic>Kidney International</italic></source><year>2004</year><volume>66</volume><issue>2</issue><fpage>518</fpage><lpage>522</lpage><pub-id pub-id-type="pmid">15253701</pub-id></citation></ref><ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lagaaij</surname><given-names>EL</given-names></name><name><surname>Cramer-Knijnenburg</surname><given-names>GF</given-names></name><name><surname>van Kemenade</surname><given-names>FJ</given-names></name><name><surname>van Es</surname><given-names>LA</given-names></name><name><surname>Bruijn</surname><given-names>JA</given-names></name><name><surname>van Krieken</surname><given-names>JHJM</given-names></name></person-group><article-title>Endothelial cell chimerism after renal transplantation and vascular rejection</article-title><source><italic>The Lancet</italic></source><year>2001</year><volume>357</volume><issue>9249</issue><fpage>33</fpage><lpage>37</lpage></citation></ref><ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>H</given-names></name><name><surname>Daig</surname><given-names>U</given-names></name><name><surname>Martini</surname><given-names>S</given-names></name><etal/></person-group><article-title>No mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis</article-title><source><italic>Kidney International</italic></source><year>2003</year><volume>64</volume><issue>2</issue><fpage>509</fpage><lpage>518</lpage><pub-id pub-id-type="pmid">12846746</pub-id></citation></ref><ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Morioka</surname><given-names>T</given-names></name><name><surname>Uchiyama</surname><given-names>M</given-names></name><name><surname>Oite</surname><given-names>T</given-names></name></person-group><article-title>Bone marrow cell infusion ameliorates progressive glomerulosclerosis in an experimental rat model</article-title><source><italic>Kidney International</italic></source><year>2006</year><volume>69</volume><issue>2</issue><fpage>323</fpage><lpage>330</lpage><pub-id pub-id-type="pmid">16408122</pub-id></citation></ref><ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uchimura</surname><given-names>H</given-names></name><name><surname>Marumo</surname><given-names>T</given-names></name><name><surname>Takase</surname><given-names>O</given-names></name><etal/></person-group><article-title>Intrarenal injection of bone marrow-derived angiogenic cells reduces endothelial injury and mesangial cell activation in experimental glomerulonephritis</article-title><source><italic>Journal of the American Society of Nephrology</italic></source><year>2005</year><volume>16</volume><issue>4</issue><fpage>997</fpage><lpage>1004</lpage><pub-id pub-id-type="pmid">15744001</pub-id></citation></ref><ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barroso</surname><given-names>I</given-names></name><name><surname>Gurnell</surname><given-names>M</given-names></name><name><surname>Crowley</surname><given-names>VEF</given-names></name><etal/></person-group><article-title>Dominant negative mutations in human PPAR<italic>&#x003b3;</italic> associated with severe insulin resistance, diabetes mellitus and hypertension</article-title><source><italic>Nature</italic></source><year>1999</year><volume>402</volume><issue>6764</issue><fpage>880</fpage><lpage>883</lpage><pub-id pub-id-type="pmid">10622252</pub-id></citation></ref><ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miles</surname><given-names>PDG</given-names></name><name><surname>Barak</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>W</given-names></name><name><surname>Evans</surname><given-names>RM</given-names></name><name><surname>Olefsky</surname><given-names>JM</given-names></name></person-group><article-title>Improved insulin-sensitivity in mice heterozygous for PPAR-<italic>&#x003b3;</italic> deficiency</article-title><source><italic>The Journal of Clinical Investigation</italic></source><year>2000</year><volume>105</volume><issue>3</issue><fpage>287</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">10675354</pub-id></citation></ref><ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamauchi</surname><given-names>T</given-names></name><name><surname>Kamon</surname><given-names>J</given-names></name><name><surname>Waki</surname><given-names>H</given-names></name><etal/></person-group><article-title>The mechanisms by which both heterozygous peroxisome proliferator-activated receptor <italic>&#x003b3;</italic> (PPAR<italic>&#x003b3;</italic>) deficiency and PPAR<italic>&#x003b3;</italic> agonist improve insulin resistance</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2001</year><volume>276</volume><issue>44</issue><fpage>41245</fpage><lpage>41254</lpage><pub-id pub-id-type="pmid">11533050</pub-id></citation></ref><ref id="B34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barak</surname><given-names>Y</given-names></name><name><surname>Nelson</surname><given-names>MC</given-names></name><name><surname>Ong</surname><given-names>ES</given-names></name><etal/></person-group><article-title>PPAR<italic>&#x003b3;</italic> is required for placental, cardiac, and adipose tissue development</article-title><source><italic>Molecular Cell</italic></source><year>1999</year><volume>4</volume><issue>4</issue><fpage>585</fpage><lpage>595</lpage><pub-id pub-id-type="pmid">10549290</pub-id></citation></ref><ref id="B35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>SZ</given-names></name><name><surname>Ivashchenko</surname><given-names>CY</given-names></name><name><surname>Whitesall</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Hypotension, lipodystrophy, and insulin resistance in generalized PPAR<italic>&#x003b3;</italic>-deficient mice rescued from embryonic lethality</article-title><source><italic>The Journal of Clinical Investigation</italic></source><year>2007</year><volume>117</volume><issue>3</issue><fpage>812</fpage><lpage>822</lpage><pub-id pub-id-type="pmid">17304352</pub-id></citation></ref><ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nicol</surname><given-names>CJ</given-names></name><name><surname>Adachi</surname><given-names>M</given-names></name><name><surname>Akiyama</surname><given-names>TE</given-names></name><name><surname>Gonzalez</surname><given-names>FJ</given-names></name></person-group><article-title>PPAR<italic>&#x003b3;</italic> in endothelial cells influences high fat diet-induced hypertension</article-title><source><italic>The American Journal of Hypertension</italic></source><year>2005</year><volume>18</volume><issue>4</issue><fpage>549</fpage><lpage>556</lpage></citation></ref><ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beyer</surname><given-names>AM</given-names></name><name><surname>Baumbach</surname><given-names>GL</given-names></name><name><surname>Halabi</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Interference with PPAR<italic>&#x003b3;</italic> signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling</article-title><source><italic>Hypertension</italic></source><year>2008</year><volume>51</volume><issue>4</issue><fpage>867</fpage><lpage>871</lpage><pub-id pub-id-type="pmid">18285614</pub-id></citation></ref><ref id="B38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Semple</surname><given-names>RK</given-names></name><name><surname>Meirhaeghe</surname><given-names>A</given-names></name><name><surname>Vidal-Puig</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>A dominant negative human peroxisome proliferator-activated receptor (PPAR)<italic>&#x003b1;</italic> is a constitutive transcriptional corepressor and inhibits signaling through all PPAR isoforms</article-title><source><italic>Endocrinology</italic></source><year>2005</year><volume>146</volume><issue>4</issue><fpage>1871</fpage><lpage>1882</lpage><pub-id pub-id-type="pmid">15661858</pub-id></citation></ref><ref id="B39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fukunaga</surname><given-names>Y</given-names></name><name><surname>Itoh</surname><given-names>H</given-names></name><name><surname>Doi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Thiazolidinediones, peroxisome proliferator-activated receptor <italic>&#x003b3;</italic> agonists, regulate endothelial cell growth and secretion of vasoactive peptides</article-title><source><italic>Atherosclerosis</italic></source><year>2001</year><volume>158</volume><issue>1</issue><fpage>113</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">11500181</pub-id></citation></ref><ref id="B40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Dios</surname><given-names>ST</given-names></name><name><surname>Hannan</surname><given-names>KM</given-names></name><name><surname>Dilley</surname><given-names>RJ</given-names></name><name><surname>Hill</surname><given-names>MA</given-names></name><name><surname>Little</surname><given-names>PJ</given-names></name></person-group><article-title>Troglitazone, but not rosiglitazone, inhibits Na/H exchange activity and proliferation of macrovascular endothelial cells</article-title><source><italic>Journal of Diabetes and Its Complications</italic></source><year>2001</year><volume>15</volume><issue>3</issue><fpage>120</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">11358680</pub-id></citation></ref><ref id="B41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>HK</given-names></name><name><surname>Cho</surname><given-names>YM</given-names></name><name><surname>Park</surname><given-names>K-H</given-names></name><name><surname>Lee</surname><given-names>C-T</given-names></name><name><surname>Lee</surname><given-names>HK</given-names></name><name><surname>Park</surname><given-names>KS</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor gamma mediated inhibition of plasminogen activator inhibitor type 1 production and proliferation of human umbilical vein endothelial cells</article-title><source><italic>Diabetes Research and Clinical Practice</italic></source><year>2003</year><volume>62</volume><issue>1</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">14581151</pub-id></citation></ref><ref id="B42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sheu</surname><given-names>WH-H</given-names></name><name><surname>Ou</surname><given-names>H-C</given-names></name><name><surname>Chou</surname><given-names>F-P</given-names></name><name><surname>Lin</surname><given-names>T-M</given-names></name><name><surname>Yang</surname><given-names>C-H</given-names></name></person-group><article-title>Rosiglitazone inhibits endothelial proliferation and angiogenesis</article-title><source><italic>Life Sciences</italic></source><year>2006</year><volume>78</volume><issue>13</issue><fpage>1520</fpage><lpage>1528</lpage><pub-id pub-id-type="pmid">16297938</pub-id></citation></ref><ref id="B43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goetze</surname><given-names>S</given-names></name><name><surname>Eilers</surname><given-names>F</given-names></name><name><surname>Bungenstock</surname><given-names>A</given-names></name><etal/></person-group><article-title>PPAR activators inhibit endothelial cell migration by targeting Akt</article-title><source><italic>Biochemical and Biophysical Research Communications</italic></source><year>2002</year><volume>293</volume><issue>5</issue><fpage>1431</fpage><lpage>1437</lpage><pub-id pub-id-type="pmid">12054675</pub-id></citation></ref><ref id="B44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xin</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Kowalski</surname><given-names>J</given-names></name><name><surname>Gerritsen</surname><given-names>ME</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor <italic>&#x003b3;</italic> ligands are potent inhibitors of angiogenesis in vitro and in vivo</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>1999</year><volume>274</volume><issue>13</issue><fpage>9116</fpage><lpage>9121</lpage><pub-id pub-id-type="pmid">10085162</pub-id></citation></ref><ref id="B45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Biscetti</surname><given-names>F</given-names></name><name><surname>Gaetani</surname><given-names>E</given-names></name><name><surname>Flex</surname><given-names>A</given-names></name><etal/></person-group><article-title>Selective activation of peroxisome proliferator-activated receptor (PPAR)<italic>&#x003b1;</italic> and PPAR<italic>&#x003b3;</italic> induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism</article-title><source><italic>Diabetes</italic></source><year>2008</year><volume>57</volume><issue>5</issue><fpage>1394</fpage><lpage>1404</lpage><pub-id pub-id-type="pmid">18268046</pub-id></citation></ref><ref id="B46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Artwohl</surname><given-names>M</given-names></name><name><surname>H&#x000f6;lzebein</surname><given-names>T</given-names></name><name><surname>F&#x000fc;rnsinn</surname><given-names>C</given-names></name><etal/></person-group><article-title>Thiazolidinediones inhibit apoptosis and heat shock protein 60 expression in human vascular endothelial cells</article-title><source><italic>Thrombosis and Haemostasis</italic></source><year>2005</year><volume>93</volume><issue>5</issue><fpage>810</fpage><lpage>815</lpage><pub-id pub-id-type="pmid">15886792</pub-id></citation></ref><ref id="B47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hannan</surname><given-names>KM</given-names></name><name><surname>Dilley</surname><given-names>RJ</given-names></name><name><surname>de Dios</surname><given-names>ST</given-names></name><name><surname>Little</surname><given-names>PJ</given-names></name></person-group><article-title>Troglitazone stimulates repair of the endothelium and inhibits neointimal formation in denuded rat aorta</article-title><source><italic>Arteriosclerosis, Thrombosis, and Vascular Biology</italic></source><year>2003</year><volume>23</volume><issue>5</issue><fpage>762</fpage><lpage>768</lpage></citation></ref><ref id="B48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bishop-Bailey</surname><given-names>D</given-names></name><name><surname>Hla</surname><given-names>T</given-names></name></person-group><article-title>Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-&#x00394;<sup>12,14</sup>-prostaglandin J<sub>2</sub></article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>1999</year><volume>274</volume><issue>24</issue><fpage>17042</fpage><lpage>17048</lpage><pub-id pub-id-type="pmid">10358055</pub-id></citation></ref><ref id="B49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levonen</surname><given-names>A-L</given-names></name><name><surname>Dickinson</surname><given-names>DA</given-names></name><name><surname>Moellering</surname><given-names>DR</given-names></name><name><surname>Mulcahy</surname><given-names>RT</given-names></name><name><surname>Forman</surname><given-names>HJ</given-names></name><name><surname>Darley-Usmar</surname><given-names>VM</given-names></name></person-group><article-title>Biphasic effects of 15-deoxy-&#x00394;<sup>12,14</sup>-prostaglandin J<sub>2</sub> on glutathione induction and apoptosis in human endothelial cells</article-title><source><italic>Arteriosclerosis, Thrombosis, and Vascular Biology</italic></source><year>2001</year><volume>21</volume><issue>11</issue><fpage>1846</fpage><lpage>1851</lpage></citation></ref><ref id="B50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Migita</surname><given-names>H</given-names></name><name><surname>Morser</surname><given-names>J</given-names></name></person-group><article-title>15-deoxy-&#x00394;<sup>12,14</sup>-postaglandin J<sub>2</sub> (15d-PGJ2) signals through retinoic acid receptor-related orphan receptor-<italic>&#x003b1;</italic> but not peroxisome proliferator-activated receptor-<italic>&#x003b3;</italic> in human vascular endothelial cells: the effect of 15d-PGJ2 on tumor necrosis factor-<italic>&#x003b1;</italic>-induced gene expression</article-title><source><italic>Arteriosclerosis, Thrombosis, and Vascular Biology</italic></source><year>2005</year><volume>25</volume><issue>4</issue><fpage>710</fpage><lpage>716</lpage></citation></ref><ref id="B51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>P-H</given-names></name><name><surname>Sata</surname><given-names>M</given-names></name><name><surname>Nishimatsu</surname><given-names>H</given-names></name><name><surname>Sumi</surname><given-names>M</given-names></name><name><surname>Hirata</surname><given-names>Y</given-names></name><name><surname>Nagai</surname><given-names>R</given-names></name></person-group><article-title>Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice</article-title><source><italic>Biomedicine and Pharmacotherapy</italic></source><year>2008</year><volume>62</volume><issue>1</issue><fpage>46</fpage><lpage>52</lpage></citation></ref><ref id="B52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>S-T</given-names></name><name><surname>Koo</surname><given-names>J-S</given-names></name><etal/></person-group><article-title>Peroxisome proliferator-activated receptor-<italic>&#x003b3;</italic>-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia</article-title><source><italic>Brain Research</italic></source><year>2006</year><volume>1093</volume><issue>1</issue><fpage>208</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">16696956</pub-id></citation></ref><ref id="B53"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murata</surname><given-names>T</given-names></name><name><surname>He</surname><given-names>S</given-names></name><name><surname>Hangai</surname><given-names>M</given-names></name><etal/></person-group><article-title>Peroxisome proliferator-activated receptor-<italic>&#x003b3;</italic> ligands inhibit choroidal neovascularization</article-title><source><italic>Investigative Ophthalmology and Visual Science</italic></source><year>2000</year><volume>41</volume><issue>8</issue><fpage>2309</fpage><lpage>2317</lpage><pub-id pub-id-type="pmid">10892878</pub-id></citation></ref><ref id="B54"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Panigrahy</surname><given-names>D</given-names></name><name><surname>Singer</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>LQ</given-names></name><etal/></person-group><article-title>PPAR<italic>&#x003b3;</italic> ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis</article-title><source><italic>The Journal of Clinical Investigation</italic></source><year>2002</year><volume>110</volume><issue>7</issue><fpage>923</fpage><lpage>932</lpage><pub-id pub-id-type="pmid">12370270</pub-id></citation></ref><ref id="B55"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keshamouni</surname><given-names>VG</given-names></name><name><surname>Arenberg</surname><given-names>DA</given-names></name><name><surname>Reddy</surname><given-names>RC</given-names></name><name><surname>Newstead</surname><given-names>MJ</given-names></name><name><surname>Anthwal</surname><given-names>S</given-names></name><name><surname>Standiford</surname><given-names>TJ</given-names></name></person-group><article-title>PPAR-<italic>&#x003b3;</italic> activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer</article-title><source><italic>Neoplasia</italic></source><year>2005</year><volume>7</volume><issue>3</issue><fpage>294</fpage><lpage>301</lpage><pub-id pub-id-type="pmid">15799829</pub-id></citation></ref><ref id="B56"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Verhaar</surname><given-names>MC</given-names></name><name><surname>Rabelink</surname><given-names>TJ</given-names></name></person-group><article-title>Endothelial function: strategies for early intervention</article-title><source><italic>Cardiovascular Drugs and Therapy</italic></source><year>1998</year><volume>12</volume><issue>supplement 1</issue><fpage>125</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">9642486</pub-id></citation></ref><ref id="B57"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calnek</surname><given-names>DS</given-names></name><name><surname>Mazzella</surname><given-names>L</given-names></name><name><surname>Roser</surname><given-names>S</given-names></name><name><surname>Roman</surname><given-names>J</given-names></name><name><surname>Hart</surname><given-names>CM</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor <italic>&#x003b3;</italic> ligands increase release of nitric oxide from endothelial cells</article-title><source><italic>Arteriosclerosis, Thrombosis, and Vascular Biology</italic></source><year>2003</year><volume>23</volume><issue>1</issue><fpage>52</fpage><lpage>57</lpage></citation></ref><ref id="B58"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goya</surname><given-names>K</given-names></name><name><surname>Sumitani</surname><given-names>S</given-names></name><name><surname>Otsuki</surname><given-names>M</given-names></name><etal/></person-group><article-title>The thiazolidinedione drug troglitazone up-regulates nitric oxide synthase expression in vascular endothelial cells</article-title><source><italic>Journal of Diabetes and Its Complications</italic></source><year>2006</year><volume>20</volume><issue>5</issue><fpage>336</fpage><lpage>342</lpage><pub-id pub-id-type="pmid">16949522</pub-id></citation></ref><ref id="B59"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Polikandriotis</surname><given-names>JA</given-names></name><name><surname>Mazzella</surname><given-names>LJ</given-names></name><name><surname>Rupnow</surname><given-names>HL</given-names></name><name><surname>Hart</surname><given-names>CM</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor <italic>&#x003b3;</italic> ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor <italic>&#x003b3;</italic>-dependent mechanisms</article-title><source><italic>Arteriosclerosis, Thrombosis, and Vascular Biology</italic></source><year>2005</year><volume>25</volume><issue>9</issue><fpage>1810</fpage><lpage>1816</lpage></citation></ref><ref id="B60"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ptasinska</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wesley</surname><given-names>RA</given-names></name><name><surname>Danner</surname><given-names>RL</given-names></name></person-group><article-title>Nitric oxide activation of peroxisome proliferator-activated receptor gamma through a p38 MAPK signaling pathway</article-title><source><italic>The FASEB Journal</italic></source><year>2007</year><volume>21</volume><issue>3</issue><fpage>950</fpage><lpage>961</lpage><pub-id pub-id-type="pmid">17197391</pub-id></citation></ref><ref id="B61"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Majithiya</surname><given-names>JB</given-names></name><name><surname>Paramar</surname><given-names>AN</given-names></name><name><surname>Balaraman</surname><given-names>R</given-names></name></person-group><article-title>Pioglitazone, a PPAR<italic>&#x003b3;</italic> agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats</article-title><source><italic>Cardiovascular Research</italic></source><year>2005</year><volume>66</volume><issue>1</issue><fpage>150</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">15769458</pub-id></citation></ref><ref id="B62"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fujishima</surname><given-names>S</given-names></name><name><surname>Ohya</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Onaka</surname><given-names>U</given-names></name><name><surname>Abe</surname><given-names>I</given-names></name><name><surname>Fujishima</surname><given-names>M</given-names></name></person-group><article-title>Troglitazone, an insulin sensitizer, increases forearm blood flow in humans</article-title><source><italic>The American Journal of Hypertension</italic></source><year>1998</year><volume>11</volume><issue>9</issue><fpage>1134</fpage><lpage>1137</lpage></citation></ref><ref id="B63"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Campia</surname><given-names>U</given-names></name><name><surname>Matuskey</surname><given-names>LA</given-names></name><name><surname>Panza</surname><given-names>JA</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor-<italic>&#x003b3;</italic> activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors</article-title><source><italic>Circulation</italic></source><year>2006</year><volume>113</volume><issue>6</issue><fpage>867</fpage><lpage>875</lpage><pub-id pub-id-type="pmid">16461819</pub-id></citation></ref><ref id="B64"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghazzi</surname><given-names>MN</given-names></name><name><surname>Perez</surname><given-names>JE</given-names></name><name><surname>Antonucci</surname><given-names>TK</given-names></name><etal/></person-group><article-title>Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group</article-title><source><italic>Diabetes</italic></source><year>1997</year><volume>46</volume><issue>3</issue><fpage>433</fpage><lpage>439</lpage><pub-id pub-id-type="pmid">9032099</pub-id></citation></ref><ref id="B65"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>BH</given-names></name><name><surname>Izzo</surname><given-names>JL</given-names><suffix>Jr.</suffix></name><name><surname>Dandona</surname><given-names>P</given-names></name><name><surname>Wilson</surname><given-names>MF</given-names></name></person-group><article-title>Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus</article-title><source><italic>Hypertension</italic></source><year>1999</year><volume>34</volume><issue>1</issue><fpage>83</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">10406828</pub-id></citation></ref><ref id="B66"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murakami</surname><given-names>T</given-names></name><name><surname>Mizuno</surname><given-names>S</given-names></name><name><surname>Ohsato</surname><given-names>K</given-names></name><etal/></person-group><article-title>Effects of <italic>troglitazone</italic> on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus</article-title><source><italic>The American Journal of Cardiology</italic></source><year>1999</year><volume>84</volume><issue>1</issue><fpage>92</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">10404859</pub-id></citation></ref><ref id="B67"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vinik</surname><given-names>AI</given-names></name><name><surname>Stansberry</surname><given-names>KB</given-names></name><name><surname>Barlow</surname><given-names>PM</given-names></name></person-group><article-title>Rosiglitazone treatment increases nitric oxide production in human peripheral skin: a controlled clinical trial in patients with type 2 diabetes mellitus</article-title><source><italic>Journal of Diabetes and Its Complications</italic></source><year>2003</year><volume>17</volume><issue>5</issue><fpage>279</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">12954157</pub-id></citation></ref><ref id="B68"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Matsuda</surname><given-names>T</given-names></name><name><surname>Kawagoe</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients</article-title><source><italic>Metabolism</italic></source><year>2004</year><volume>53</volume><issue>10</issue><fpage>1382</fpage><lpage>1386</lpage><pub-id pub-id-type="pmid">15375799</pub-id></citation></ref><ref id="B69"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Voytovich</surname><given-names>MH</given-names></name><name><surname>Simonsen</surname><given-names>C</given-names></name><name><surname>Jenssen</surname><given-names>T</given-names></name><name><surname>Hjelmes&#x000e6;th</surname><given-names>J</given-names></name><name><surname>&#x000c5;sberg</surname><given-names>A</given-names></name><name><surname>Hartmann</surname><given-names>A</given-names></name></person-group><article-title>Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients</article-title><source><italic>Nephrology Dialysis Transplantation</italic></source><year>2005</year><volume>20</volume><issue>2</issue><fpage>413</fpage><lpage>418</lpage></citation></ref><ref id="B70"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pistrosch</surname><given-names>F</given-names></name><name><surname>Herbrig</surname><given-names>K</given-names></name><name><surname>Kindel</surname><given-names>B</given-names></name><name><surname>Passauer</surname><given-names>J</given-names></name><name><surname>Fischer</surname><given-names>S</given-names></name><name><surname>Gross</surname><given-names>P</given-names></name></person-group><article-title>Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients</article-title><source><italic>Diabetes</italic></source><year>2005</year><volume>54</volume><issue>7</issue><fpage>2206</fpage><lpage>2211</lpage><pub-id pub-id-type="pmid">15983223</pub-id></citation></ref><ref id="B71"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fujiwara</surname><given-names>K</given-names></name><name><surname>Hayashi</surname><given-names>K</given-names></name><name><surname>Matsuda</surname><given-names>H</given-names></name><etal/></person-group><article-title>Altered pressure-natriuresis in obese Zucker rats</article-title><source><italic>Hypertension</italic></source><year>1999</year><volume>33</volume><issue>6</issue><fpage>1470</fpage><lpage>1475</lpage><pub-id pub-id-type="pmid">10373235</pub-id></citation></ref><ref id="B72"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dobrian</surname><given-names>AD</given-names></name><name><surname>Schriver</surname><given-names>SD</given-names></name><name><surname>Khraibi</surname><given-names>AA</given-names></name><name><surname>Prewitt</surname><given-names>RL</given-names></name></person-group><article-title>Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity</article-title><source><italic>Hypertension</italic></source><year>2004</year><volume>43</volume><issue>1</issue><fpage>48</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">14638618</pub-id></citation></ref><ref id="B73"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Govers</surname><given-names>R</given-names></name><name><surname>Rabelink</surname><given-names>TJ</given-names></name></person-group><article-title>Cellular regulation of endothelial nitric oxide synthase</article-title><source><italic>The American Journal of Physiology</italic></source><year>2001</year><volume>280</volume><issue>2</issue><fpage>F193</fpage><lpage>F206</lpage></citation></ref><ref id="B74"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Braam</surname><given-names>B</given-names></name><name><surname>Verhaar</surname><given-names>MC</given-names></name></person-group><article-title>Understanding eNOS for pharmacological modulation of endothelial function: a translational view</article-title><source><italic>Current Pharmaceutical Design</italic></source><year>2007</year><volume>13</volume><issue>17</issue><fpage>1727</fpage><lpage>1740</lpage><pub-id pub-id-type="pmid">17584103</pub-id></citation></ref><ref id="B75"><label>75</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gonon</surname><given-names>AT</given-names></name><name><surname>Bulhak</surname><given-names>A</given-names></name><name><surname>Labruto</surname><given-names>F</given-names></name><name><surname>Sj&#x000f6;quist</surname><given-names>P-O</given-names></name><name><surname>Pernow</surname><given-names>J</given-names></name></person-group><article-title>Cardioprotection mediated by rosiglitazone, a peroxisome proliferator activated receptor gamma ligand, in relation to nitric oxide</article-title><source><italic>Basic Research in Cardiology</italic></source><year>2007</year><volume>102</volume><issue>1</issue><fpage>80</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">16900441</pub-id></citation></ref><ref id="B76"><label>76</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ingbir</surname><given-names>M</given-names></name><name><surname>Schwartz</surname><given-names>IF</given-names></name><name><surname>Shtabsky</surname><given-names>A</given-names></name><etal/></person-group><article-title>Rosiglitazone improves aortic arginine transport, through inhibition of PKC<italic>&#x003b1;</italic>, in uremic rats</article-title><source><italic>The American Journal of Physiology</italic></source><year>2008</year><volume>295</volume><issue>2</issue><fpage>F471</fpage><lpage>F477</lpage></citation></ref><ref id="B77"><label>77</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>IF</given-names></name><name><surname>Ayalon</surname><given-names>R</given-names></name><name><surname>Chernichovski</surname><given-names>T</given-names></name><etal/></person-group><article-title>Arginine uptake is attenuated through modulation of cationic amino-acid transporter-1, in uremic rats</article-title><source><italic>Kidney International</italic></source><year>2006</year><volume>69</volume><issue>2</issue><fpage>298</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">16408119</pub-id></citation></ref><ref id="B78"><label>78</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>L</given-names></name><name><surname>Klein</surname><given-names>JD</given-names></name><name><surname>Sands</surname><given-names>JM</given-names></name><name><surname>Baylis</surname><given-names>C</given-names></name></person-group><article-title>Urea transporters are distributed in endothelial cells and mediate inhibition of L-arginine transport</article-title><source><italic>The American Journal of Physiology</italic></source><year>2002</year><volume>283</volume><issue>3</issue><fpage>F578</fpage><lpage>F582</lpage></citation></ref><ref id="B79"><label>79</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>S</given-names></name><name><surname>Wagner</surname><given-names>L</given-names></name><name><surname>Mahaney</surname><given-names>J</given-names></name><name><surname>Baylis</surname><given-names>C</given-names></name></person-group><article-title>Uremic levels of urea inhibit L-arginine transport in cultured endothelial cells</article-title><source><italic>The American Journal of Physiology</italic></source><year>2001</year><volume>280</volume><issue>6</issue><fpage>F989</fpage><lpage>F995</lpage></citation></ref><ref id="B80"><label>80</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>I</given-names></name><name><surname>Goto</surname><given-names>S-I</given-names></name><name><surname>Matsunaga</surname><given-names>T</given-names></name><etal/></person-group><article-title>The ligands/activators for peroxisome proliferator-activated receptor <italic>&#x003b1;</italic> (PPAR<italic>&#x003b1;</italic>) and PPAR<italic>&#x003b3;</italic> increase Cu2<sup>+</sup>,Zn2<sup>+</sup>-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells</article-title><source><italic>Metabolism</italic></source><year>2001</year><volume>50</volume><issue>1</issue><fpage>3</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">11172467</pub-id></citation></ref><ref id="B81"><label>81</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>J</given-names></name><name><surname>Kleinhenz</surname><given-names>DJ</given-names></name><name><surname>Lass&#x000e8;gue</surname><given-names>B</given-names></name><name><surname>Griendling</surname><given-names>KK</given-names></name><name><surname>Dikalov</surname><given-names>S</given-names></name><name><surname>Hart</surname><given-names>CM</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor-<italic>&#x003b3;</italic> ligands regulate endothelial membrane superoxide production</article-title><source><italic>The American Journal of Physiology</italic></source><year>2005</year><volume>288</volume><issue>4</issue><fpage>C899</fpage><lpage>C905</lpage></citation></ref><ref id="B82"><label>82</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>JL</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>D</given-names></name></person-group><article-title>Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation</article-title><source><italic>Arteriosclerosis, Thrombosis, and Vascular Biology</italic></source><year>2003</year><volume>23</volume><issue>12</issue><fpage>2203</fpage><lpage>2208</lpage></citation></ref><ref id="B83"><label>83</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Majithiya</surname><given-names>JB</given-names></name><name><surname>Parmar</surname><given-names>AN</given-names></name><name><surname>Trivedi</surname><given-names>CJ</given-names></name><name><surname>Balaraman</surname><given-names>R</given-names></name></person-group><article-title>Effect of pioglitazone on L-NAME induced hypertension in diabetic rats</article-title><source><italic>Vascular Pharmacology</italic></source><year>2005</year><volume>43</volume><issue>4</issue><fpage>260</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">16168716</pub-id></citation></ref><ref id="B84"><label>84</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sarafidis</surname><given-names>PA</given-names></name><name><surname>Lasaridis</surname><given-names>AN</given-names></name></person-group><article-title>Actions of peroxisome proliferator-activated receptors-<italic>&#x003b3;</italic> agonists explaining a possible blood pressure-lowering effect</article-title><source><italic>The American Journal of Hypertension</italic></source><year>2006</year><volume>19</volume><issue>6</issue><fpage>646</fpage><lpage>653</lpage></citation></ref><ref id="B85"><label>85</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schiffrin</surname><given-names>EL</given-names></name></person-group><article-title>Role of endothelin-1 in hypertension and vascular disease</article-title><source><italic>The American Journal of Hypertension</italic></source><year>2001</year><volume>14</volume><issue>6, part 2</issue><fpage>83S</fpage><lpage>89S</lpage></citation></ref><ref id="B86"><label>86</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martin-Nizard</surname><given-names>F</given-names></name><name><surname>Furman</surname><given-names>C</given-names></name><name><surname>Delerive</surname><given-names>P</given-names></name><etal/></person-group><article-title>Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells</article-title><source><italic>Journal of Cardiovascular Pharmacology</italic></source><year>2002</year><volume>40</volume><issue>6</issue><fpage>822</fpage><lpage>831</lpage><pub-id pub-id-type="pmid">12451315</pub-id></citation></ref><ref id="B87"><label>87</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Satoh</surname><given-names>H</given-names></name><name><surname>Tsukamoto</surname><given-names>K</given-names></name><name><surname>Hashimoto</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPAR<italic>&#x003b3;</italic> on vascular endothelial function</article-title><source><italic>Biochemical and Biophysical Research Communications</italic></source><year>1999</year><volume>254</volume><issue>3</issue><fpage>757</fpage><lpage>763</lpage><pub-id pub-id-type="pmid">9920814</pub-id></citation></ref><ref id="B88"><label>88</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Delerive</surname><given-names>P</given-names></name><name><surname>Martin-Nizard</surname><given-names>F</given-names></name><name><surname>Chinetti</surname><given-names>G</given-names></name><etal/></person-group><article-title>Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway</article-title><source><italic>Circulation Research</italic></source><year>1999</year><volume>85</volume><issue>5</issue><fpage>394</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">10473669</pub-id></citation></ref><ref id="B89"><label>89</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Ushiyama</surname><given-names>C</given-names></name><name><surname>Shimada</surname><given-names>N</given-names></name><name><surname>Hayashi</surname><given-names>K</given-names></name><name><surname>Ebihara</surname><given-names>I</given-names></name><name><surname>Koide</surname><given-names>H</given-names></name></person-group><article-title>Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients</article-title><source><italic>Journal of Diabetes and Its Complications</italic></source><year>2000</year><volume>14</volume><issue>5</issue><fpage>250</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">11113686</pub-id></citation></ref><ref id="B90"><label>90</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iglarz</surname><given-names>M</given-names></name><name><surname>Touyz</surname><given-names>RM</given-names></name><name><surname>Amiri</surname><given-names>F</given-names></name><name><surname>Lavoie</surname><given-names>M-F</given-names></name><name><surname>Diep</surname><given-names>QN</given-names></name><name><surname>Schiffrin</surname><given-names>EL</given-names></name></person-group><article-title>Effect of peroxisome proliferator-activated receptor-<italic>&#x003b1;</italic> and -<italic>&#x003b3;</italic> activators on vascular remodeling in endothelin-dependent hypertension</article-title><source><italic>Arteriosclerosis, Thrombosis, and Vascular Biology</italic></source><year>2003</year><volume>23</volume><issue>1</issue><fpage>45</fpage><lpage>51</lpage></citation></ref><ref id="B91"><label>91</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>M&#x000fc;nzel</surname><given-names>T</given-names></name><name><surname>Hink</surname><given-names>U</given-names></name><name><surname>Heitzer</surname><given-names>T</given-names></name><name><surname>Meinertz</surname><given-names>T</given-names></name></person-group><article-title>Role for NADPH/NADH oxidase in the modulation of vascular tone</article-title><source><italic>Annals of the New York Academy of Sciences</italic></source><year>1999</year><volume>874</volume><fpage>386</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">10415549</pub-id></citation></ref><ref id="B92"><label>92</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tham</surname><given-names>DM</given-names></name><name><surname>Martin-McNulty</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Y-X</given-names></name><etal/></person-group><article-title>Angiotensin II is associated with activation of NF-<italic>&#x003ba;</italic>B-mediated genes and downregulation of PPARs</article-title><source><italic>Physiological Genomics</italic></source><year>2003</year><volume>11</volume><issue>1</issue><fpage>21</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">12361987</pub-id></citation></ref><ref id="B93"><label>93</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diep</surname><given-names>QN</given-names></name><name><surname>El Mabrouk</surname><given-names>M</given-names></name><name><surname>Cohn</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-<italic>&#x003b3;</italic></article-title><source><italic>Circulation</italic></source><year>2002</year><volume>105</volume><issue>19</issue><fpage>2296</fpage><lpage>2302</lpage><pub-id pub-id-type="pmid">12010913</pub-id></citation></ref><ref id="B94"><label>94</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kintscher</surname><given-names>U</given-names></name><name><surname>Unger</surname><given-names>T</given-names></name></person-group><article-title>Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers</article-title><source><italic>Acta Diabetologica</italic></source><year>2005</year><volume>42</volume><issue>supplement 1</issue><fpage>S26</fpage><lpage>S32</lpage><pub-id pub-id-type="pmid">15868116</pub-id></citation></ref><ref id="B95"><label>95</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Verna</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>N-G</given-names></name><etal/></person-group><article-title>Constitutive activation of peroxisome proliferator-activated receptor-<italic>&#x003b3;</italic> suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2002</year><volume>277</volume><issue>37</issue><fpage>34176</fpage><lpage>34181</lpage><pub-id pub-id-type="pmid">12107164</pub-id></citation></ref><ref id="B96"><label>96</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>SM</given-names></name><name><surname>Parhami</surname><given-names>F</given-names></name><name><surname>Xi</surname><given-names>X-P</given-names></name><etal/></person-group><article-title>Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction</article-title><source><italic>Arteriosclerosis, Thrombosis, and Vascular Biology</italic></source><year>1999</year><volume>19</volume><issue>9</issue><fpage>2094</fpage><lpage>2104</lpage></citation></ref><ref id="B97"><label>97</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>S</given-names></name><name><surname>Choi</surname><given-names>C</given-names></name></person-group><article-title>Peroxisome proliferator activated receptor <italic>&#x003b3;</italic> agonists suppress TNF<italic>&#x003b1;</italic>-induced ICAM-1 expression by endothelial cells in a manner potentially dependent on inhibition of reactive oxygen species</article-title><source><italic>Immunology Letters</italic></source><year>2008</year><volume>117</volume><issue>1</issue><fpage>63</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">18206249</pub-id></citation></ref><ref id="B98"><label>98</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marx</surname><given-names>N</given-names></name><name><surname>Mach</surname><given-names>F</given-names></name><name><surname>Sauty</surname><given-names>A</given-names></name><etal/></person-group><article-title>Peroxisome proliferator-activated receptor-<italic>&#x003b3;</italic> activators inhibit IFN-<italic>&#x003b3;</italic>-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells</article-title><source><italic>The Journal of Immunology</italic></source><year>2000</year><volume>164</volume><issue>12</issue><fpage>6503</fpage><lpage>6508</lpage><pub-id pub-id-type="pmid">10843708</pub-id></citation></ref><ref id="B99"><label>99</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Imamoto</surname><given-names>E</given-names></name><name><surname>Yoshida</surname><given-names>N</given-names></name><name><surname>Uchiyama</surname><given-names>K</given-names></name><etal/></person-group><article-title>Inhibitory effect of pioglitazone on expression of adhesion molecules on neutrophils and endothelial cells</article-title><source><italic>BioFactors</italic></source><year>2004</year><volume>20</volume><issue>1</issue><fpage>37</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">15096659</pub-id></citation></ref><ref id="B100"><label>100</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tesse</surname><given-names>A</given-names></name><name><surname>Al-Massarani</surname><given-names>G</given-names></name><name><surname>Wangensteen</surname><given-names>R</given-names></name><name><surname>Reitenbach</surname><given-names>S</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>MC</given-names></name><name><surname>Andriantsitohaina</surname><given-names>R</given-names></name></person-group><article-title>Rosiglitazone, a peroxisome proliferator-activated receptor-<italic>&#x003b3;</italic> agonist, prevents microparticle-induced vascular hyporeactivity through the regulation of proinflammatory proteins</article-title><source><italic>Journal of Pharmacology and Experimental Therapeutics</italic></source><year>2008</year><volume>324</volume><issue>2</issue><fpage>539</fpage><lpage>547</lpage><pub-id pub-id-type="pmid">18039959</pub-id></citation></ref><ref id="B101"><label>101</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Verrier</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wadham</surname><given-names>C</given-names></name><etal/></person-group><article-title>PPAR<italic>&#x003b3;</italic> agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway: role of diacylglycerol kinase</article-title><source><italic>Circulation Research</italic></source><year>2004</year><volume>94</volume><issue>11</issue><fpage>1515</fpage><lpage>1522</lpage><pub-id pub-id-type="pmid">15117825</pub-id></citation></ref><ref id="B102"><label>102</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramirez</surname><given-names>SH</given-names></name><name><surname>Heilman</surname><given-names>D</given-names></name><name><surname>Morsey</surname><given-names>B</given-names></name><name><surname>Potula</surname><given-names>R</given-names></name><name><surname>Haorah</surname><given-names>J</given-names></name><name><surname>Persidsky</surname><given-names>Y</given-names></name></person-group><article-title>Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) suppresses Rho GTPases in human brain microvascular endothelial cells and inhibits adhesion and transendothelial migration of HIV-1 infected monocytes</article-title><source><italic>The Journal of Immunology</italic></source><year>2008</year><volume>180</volume><issue>3</issue><fpage>1854</fpage><lpage>1865</lpage><pub-id pub-id-type="pmid">18209083</pub-id></citation></ref><ref id="B103"><label>103</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pasceri</surname><given-names>V</given-names></name><name><surname>Wu</surname><given-names>HD</given-names></name><name><surname>Willerson</surname><given-names>JT</given-names></name><name><surname>Yeh</surname><given-names>ETH</given-names></name></person-group><article-title>Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-<italic>&#x003b3;</italic> activators</article-title><source><italic>Circulation</italic></source><year>2000</year><volume>101</volume><issue>3</issue><fpage>235</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">10645917</pub-id></citation></ref><ref id="B104"><label>104</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C-H</given-names></name><name><surname>Ciliberti</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>S-H</given-names></name><etal/></person-group><article-title>Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy</article-title><source><italic>Circulation</italic></source><year>2004</year><volume>109</volume><issue>11</issue><fpage>1392</fpage><lpage>1400</lpage><pub-id pub-id-type="pmid">14993120</pub-id></citation></ref><ref id="B105"><label>105</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gensch</surname><given-names>C</given-names></name><name><surname>Clever</surname><given-names>YP</given-names></name><name><surname>Werner</surname><given-names>C</given-names></name><name><surname>Hanhoun</surname><given-names>M</given-names></name><name><surname>B&#x000f6;hm</surname><given-names>M</given-names></name><name><surname>Laufs</surname><given-names>U</given-names></name></person-group><article-title>The PPAR-<italic>&#x003b3;</italic> agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells</article-title><source><italic>Atherosclerosis</italic></source><year>2007</year><volume>192</volume><issue>1</issue><fpage>67</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">16876172</pub-id></citation></ref><ref id="B106"><label>106</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pistrosch</surname><given-names>F</given-names></name><name><surname>Herbrig</surname><given-names>K</given-names></name><name><surname>Oelschlaegel</surname><given-names>U</given-names></name><etal/></person-group><article-title>PPAR<italic>&#x003b3;</italic>-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells</article-title><source><italic>Atherosclerosis</italic></source><year>2005</year><volume>183</volume><issue>1</issue><fpage>163</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">15907852</pub-id></citation></ref><ref id="B107"><label>107</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Werner</surname><given-names>C</given-names></name><name><surname>Kamani</surname><given-names>CH</given-names></name><name><surname>Gensch</surname><given-names>C</given-names></name><name><surname>B&#x000f6;hm</surname><given-names>M</given-names></name><name><surname>Laufs</surname><given-names>U</given-names></name></person-group><article-title>The peroxisome proliferator-activated receptor-<italic>&#x003b3;</italic> agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance</article-title><source><italic>Diabetes</italic></source><year>2007</year><volume>56</volume><issue>10</issue><fpage>2609</fpage><lpage>2615</lpage><pub-id pub-id-type="pmid">17623816</pub-id></citation></ref><ref id="B108"><label>108</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Redondo</surname><given-names>S</given-names></name><name><surname>Hristov</surname><given-names>M</given-names></name><name><surname>G&#x000fc;mbel</surname><given-names>D</given-names></name><name><surname>Tejerina</surname><given-names>T</given-names></name><name><surname>Weber</surname><given-names>C</given-names></name></person-group><article-title>Biphasic effect of pioglitazone on isolated human endothelial progenitor cells: involvement of peroxisome proliferator-activated receptor-<italic>&#x003b3;</italic> and transforming growth factor-<italic>&#x003b2;</italic>1</article-title><source><italic>Thrombosis and Haemostasis</italic></source><year>2007</year><volume>97</volume><issue>6</issue><fpage>979</fpage><lpage>987</lpage><pub-id pub-id-type="pmid">17549301</pub-id></citation></ref><ref id="B109"><label>109</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Verma</surname><given-names>S</given-names></name><name><surname>Kuliszewski</surname><given-names>MA</given-names></name><name><surname>Li</surname><given-names>S-H</given-names></name><etal/></person-group><article-title>C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease</article-title><source><italic>Circulation</italic></source><year>2004</year><volume>109</volume><issue>17</issue><fpage>2058</fpage><lpage>2067</lpage><pub-id pub-id-type="pmid">15078802</pub-id></citation></ref><ref id="B110"><label>110</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Imanishi</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Kuroi</surname><given-names>A</given-names></name><name><surname>Ikejima</surname><given-names>H</given-names></name><name><surname>Akasaka</surname><given-names>T</given-names></name></person-group><article-title>Pioglitazone inhibits angiotensin II-induced senescene of endothelial progenitor cell</article-title><source><italic>Hypertension Research</italic></source><year>2008</year><volume>31</volume><issue>4</issue><fpage>757</fpage><lpage>765</lpage><pub-id pub-id-type="pmid">18633188</pub-id></citation></ref><ref id="B111"><label>111</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bishop-Bailey</surname><given-names>D</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor <italic>&#x003b2;</italic>/<italic>&#x003b4;</italic> goes vascular</article-title><source><italic>Circulation Research</italic></source><year>2008</year><volume>102</volume><issue>2</issue><fpage>146</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">18239142</pub-id></citation></ref><ref id="B112"><label>112</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piqueras</surname><given-names>L</given-names></name><name><surname>Reynolds</surname><given-names>AR</given-names></name><name><surname>Hodivala-Dilke</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Activation of PPAR<italic>&#x003b2;</italic>/<italic>&#x003b4;</italic> induces endothelial cell proliferation and angiogenesis</article-title><source><italic>Arteriosclerosis, Thrombosis, and Vascular Biology</italic></source><year>2007</year><volume>27</volume><issue>1</issue><fpage>63</fpage><lpage>69</lpage></citation></ref><ref id="B113"><label>113</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>JK</given-names></name><name><surname>Lee</surname><given-names>HS</given-names></name><name><surname>Yang</surname><given-names>HM</given-names></name><etal/></person-group><article-title>Peroxisome proliferator-activated receptor-delta agonist enhances vasculogenesis by regulating endothelial progenitor cells through genomic and nongenomic activations of the phosphatidylinositol 3-kinase/Akt pathway</article-title><source><italic>Circulation</italic></source><year>2008</year><volume>118</volume><issue>10</issue><fpage>1021</fpage><lpage>1033</lpage><pub-id pub-id-type="pmid">18711014</pub-id></citation></ref><ref id="B114"><label>114</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rival</surname><given-names>Y</given-names></name><name><surname>Ben&#x000e9;teau</surname><given-names>N</given-names></name><name><surname>Taillandier</surname><given-names>T</given-names></name><etal/></person-group><article-title>PPAR<italic>&#x003b1;</italic> and PPAR<italic>&#x003b4;</italic> activators inhibit cytokine-induced nuclear translocation of NF-<italic>&#x003ba;</italic>B and expression of VCAM-1 in EAhy926 endothelial cells</article-title><source><italic>European Journal of Pharmacology</italic></source><year>2002</year><volume>435</volume><issue>2-3</issue><fpage>143</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">11821020</pub-id></citation></ref></ref-list></back></article>